Dr. Mitchell Bamberger MD
Attending Physician, TRICOUNTY MEDICAL ASSOCIATES INC
Member of the Healthcare Council
Council Member Biography
Mitchell Bamberger, MD, MBA, FACS, is an Associate Professor of Surgery at the University of Massachusetts Medical School in Worcester and an Attending Physician at TriCounty Urology Associates and Milford Regional Medical Center. Previously, Dr. Bamberger was the Chief of Urology at Saint Vincent Hospital, a 299 bed acute care teaching hospital in Worcester. He has extensive clinical trial investigational experience with the pharmaceutical industry as well being a consultant to a number of medical device manufacturers. Dr. Bamberger is a board member of the Massachusetts Association of Practicing Urologists. He is a reviewer for the journal Urology and has authored over 50 articles, abstracts, and book chapters. (This is me - Update Profile)
Employment History
- 2007 - 2008
- Attending Physician, UROLOGY ASSOCIATES OF ESSEX NORTH INC
- 2004 - Unspecified
- Attending Physician, TRICOUNTY MEDICAL ASSOCIATES INC
- 1999 - 2007
- Division Director of Urology, FALLON MEDICAL MANAGEMENT CO., INC.
- 1999 - 2007
- Chief of Urology, SAINT VINCENT HOSPITAL, L.L.C.
- 1999 - Unspecified
- Associate Professor of Surgery, University of Massachusetts Medical School (UMMS)
GLG NewsSM Analyses by Mitchell Bamberger(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Prostate Cancer Genetic Testing - Is it real or is it boutique lab work?
January 20, 2009
Clarient Launches Gene Expression Test for Prostate Cancer | www.medcompare.com
Genetic testing for clinically significant prostate cancer is vital to allow clinicians to treat patients. This appears to be a step in the right direction, although it does not seem this will have a major impact for the majority of cases. The study represents only a small subgroup of patients that may have some benefit from this new molecular biology test.
-
Intermittent hormonal therapy for Prostate Cancer: Is it here yet?
January 2, 2009
Finnish Multicenter Study Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer | www.medicalnewstoday.com
prostate cancer, hormonal therapy, intermittent treatemtent
-
Prostate cancer DNA vaccine trial - a necessary step
December 29, 2008
Approval From The Swedish Medical Products Agency To Start A Clinical Trial Using A Xenogenic PSA DNA Vaccine | www.medicalnewstoday.com
prostate cancer, vaccine, dna
-
Robotic Prostatectomy ?Too soon to tell?
May 29, 2008
Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
The data gives a mixed review regarding the robotic assisted radical prostatectomy for prostate cancer. There is a clear advantage in regards to a significantly decreased risk of bleeding, post operative pain, and earlier return to normal activities. However, the data does not show a clinical advantage in cancer cure or clinically significant improvement in cancer control. Much more data is needed over a longer period of time. The article does not mention surgeon experience, i.e. those who have done many robotic prostatectomies vs. a surgeon with a limited experience. Nor does the article mention post operative complications such as preservation of erectile function and continence control.
-
Novel immunotherapy for prostate cancer
April 16, 2008
Cell Genesys Announces Encouraging Results from Phase 1/2 Trial of GVAX Immunotherapy for Prostate Cancer in Recurrent Disease | www.pipelinereview.com
Novel therapy for advance recurrent prostate cancer that does not rely upon traditional standard hormone therapy. This has the potential for men to continue to be sexually active while receiving treatment for advanced disease. It also opens the door to other therapeutic interventions.
Leading institutions connect with Mitchell Bamberger through GLG
GLG Study Groups with Mitchell Bamberger(?)
GLG Live Meetings with Mitchell Bamberger(?)
Mitchell Bamberger has not participated in any GLG Live Meetings.